Market Share Purchase

RNS Number : 1612A

Oxford Biomedica PLC

31 January 2022

 

Market Share Purchase

London, UK - 31 January 2022: Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy group, was informed that Matthew Treagus, Chief Information Officer, has purchased 594 ordinary shares of 50p each ("Ordinary Shares") in the Company on 28 January 2022 on the London Stock Exchange at a price of 841.7p. Following this purchase Matthew Treagus holds 4,501 Ordinary Shares representing 0.005% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of ordinary shares purchased.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Matthew Treagus
2.	Reason for the notification
a)	Position/status	Chief Information Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Purchase
c)	Price(s) and volumes(s)	Price(s) Volume(s) £8.417 594
d)	Aggregated information · Aggregated volume · Price · Aggregated total	594  8.41664  4,999.48
e)	Date of the transaction	01-28-2022
f)	Place of the transaction	London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, Arcellx and Cabaletta Bio,through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740

people. Further information is available at www.oxb.com

 

END

 

 

DSHUAAARUNUAOAR